{"id":"https://openalex.org/W2038460733","doi":"https://doi.org/10.1161/01.hyp.27.3.426","title":"Antihypertensive Properties of the Novel Calcium Antagonist Mibefradil (Ro 40-5967)","display_name":"Antihypertensive Properties of the Novel Calcium Antagonist Mibefradil (Ro 40-5967)","publication_year":1996,"publication_date":"1996-03-01","ids":{"openalex":"https://openalex.org/W2038460733","doi":"https://doi.org/10.1161/01.hyp.27.3.426","mag":"2038460733","pmid":"https://pubmed.ncbi.nlm.nih.gov/8698449"},"language":"en","primary_location":{"id":"doi:10.1161/01.hyp.27.3.426","doi":"https://doi.org/10.1161/01.hyp.27.3.426","is_oa":false,"landing_page_url":"https://doi.org/10.1161/01.hyp.27.3.426","pdf_url":null,"source":{"id":"https://openalex.org/S67880631","display_name":"Hypertension","issn_l":"0194-911X","issn":["0194-911X","1524-4563"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hypertension","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015291437","display_name":"Peter J. L. M. Bernink","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110920","display_name":"Martini Ziekenhuis","ror":"https://ror.org/017b69w10","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I4210110920"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Peter J.L.M. Bernink","raw_affiliation_strings":["Martini Ziekenhuis, Groningen, The Netherlands","Peter J.L.M. Bernink"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Martini Ziekenhuis, Groningen, The Netherlands","institution_ids":["https://openalex.org/I4210110920"]},{"raw_affiliation_string":"Peter J.L.M. Bernink","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038334681","display_name":"Gerold Prager","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gerold Prager","raw_affiliation_strings":["Gerold Prager"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gerold Prager","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110071889","display_name":"A. Schelling","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Arie Schelling","raw_affiliation_strings":["Arie Schelling"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arie Schelling","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039593862","display_name":"Isaac Kobrin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Isaac Kobrin","raw_affiliation_strings":["Isaac Kobrin"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Isaac Kobrin","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":19.0074,"has_fulltext":false,"cited_by_count":91,"citation_normalized_percentile":{"value":0.99479786,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"27","issue":"3","first_page":"426","last_page":"432"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10493","display_name":"Ion channel regulation and function","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10217","display_name":"Cardiac electrophysiology and arrhythmias","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mibefradil","display_name":"mibefradil","score":0.9990000128746033},{"id":"https://openalex.org/keywords/calcium-channel-blockers","display_name":"calcium channel blockers","score":0.7870000004768372},{"id":"https://openalex.org/keywords/antihypertensive-drugs","display_name":"antihypertensive drugs","score":0.8190000057220459},{"id":"https://openalex.org/keywords/blood-pressure-reduction","display_name":"blood pressure reduction","score":0.9399999976158142},{"id":"https://openalex.org/keywords/heart-rate","display_name":"heart rate","score":0.8899999856948853},{"id":"https://openalex.org/keywords/pr-interval","display_name":"PR interval","score":0.746999979019165},{"id":"https://openalex.org/keywords/concentration-response-relationship","display_name":"concentration-dependent effects","score":0.8320000171661377},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.875},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7559999823570251},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.652999997138977}],"concepts":[{"id":"https://openalex.org/C2778673320","wikidata":"https://www.wikidata.org/wiki/Q6827783","display_name":"Mibefradil","level":4,"score":0.9718648791313171},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.7075730562210083},{"id":"https://openalex.org/C519063684","wikidata":"https://www.wikidata.org/wiki/Q706","display_name":"Calcium","level":2,"score":0.633906364440918},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4718461036682129},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4666127562522888},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4650508165359497},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.42980632185935974},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.42744317650794983},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.23703375458717346}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002121","descriptor_name":"Calcium Channel Blockers","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006339","descriptor_name":"Heart Rate","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006973","descriptor_name":"Hypertension","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013764","descriptor_name":"Tetrahydronaphthalenes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D020748","descriptor_name":"Mibefradil","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1161/01.hyp.27.3.426","doi":"https://doi.org/10.1161/01.hyp.27.3.426","is_oa":false,"landing_page_url":"https://doi.org/10.1161/01.hyp.27.3.426","pdf_url":null,"source":{"id":"https://openalex.org/S67880631","display_name":"Hypertension","issn_l":"0194-911X","issn":["0194-911X","1524-4563"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hypertension","raw_type":"journal-article"},{"id":"pmid:8698449","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8698449","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hypertension (Dallas, Tex. : 1979)","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W1968598458","https://openalex.org/W1980794949","https://openalex.org/W1982874313","https://openalex.org/W1986245421","https://openalex.org/W1989649753","https://openalex.org/W1998104311","https://openalex.org/W2016955566","https://openalex.org/W2017554908","https://openalex.org/W2018121375","https://openalex.org/W2027157785","https://openalex.org/W2034877370","https://openalex.org/W2037856128","https://openalex.org/W2046725590","https://openalex.org/W2052879994","https://openalex.org/W2054111689","https://openalex.org/W2076123097","https://openalex.org/W2083681760","https://openalex.org/W2129413040","https://openalex.org/W2145270758","https://openalex.org/W2170364275","https://openalex.org/W2397280942","https://openalex.org/W2413177606","https://openalex.org/W2416290411","https://openalex.org/W4249706322"],"related_works":["https://openalex.org/W1982690791","https://openalex.org/W1999596364","https://openalex.org/W2332424915","https://openalex.org/W2123663550","https://openalex.org/W2163367728","https://openalex.org/W1991756367","https://openalex.org/W2042964099","https://openalex.org/W1604087062","https://openalex.org/W28980388","https://openalex.org/W2040569221"],"abstract_inverted_index":{"Preclinical":[0],"and":[1,68,76,79,113,119,135,154,165,180,196,205,221,242],"initial":[2],"clinical":[3],"studies":[4],"suggest":[5],"that":[6,191],"the":[7,87,99,175,218,229,238],"novel":[8],"calcium":[9],"antagonist":[10],"mibefradil":[11,57,123,146,192],"has":[12],"a":[13,22,33,61,126,136,158],"unique":[14],"combination":[15],"of":[16,32,50,89,145,202,212,252],"properties.":[17],"Mibefredil":[18],"was":[19,115,147,155,172,225,234],"evaluated":[20,95],"in":[21,109,121,162,167,217,228,237],"multicenter,":[23],"double-blind,":[24],"placebo-controlled,":[25],"parallel":[26],"group":[27,247],"trial.":[28],"After":[29],"4":[30,64],"weeks":[31,153],"placebo":[34,59,230],"run-in":[35],"period,":[36],"202":[37],"eligible":[38],"patients":[39,244],"with":[40,125,157],"mild":[41],"to":[42,47,81,151],"moderate":[43],"hypertension":[44],"were":[45,71,94,186,248],"randomized":[46],"receive":[48],"doses":[49,201],"25,":[51,203],"50,":[52,204],"100,":[53],"or":[54,58],"150":[55],"mg":[56,207],"once":[60,208],"day":[62],"for":[63],"weeks.":[65],"Blood":[66],"pressure":[67,111,179],"heart":[69,163],"rate":[70,164],"measured":[72],"repeatedly":[73],"at":[74,86,96,117,200],"trough":[75,97,118],"peak":[77,120],"(24":[78],"2":[80,152],"6":[82],"hours":[83],"postdose,":[84],"respectively)":[85],"end":[88],"each":[90],"period.":[91],"Concentration-effect":[92],"relationships":[93,185],"on":[98,177],"last":[100],"treatment":[101],"day.":[102],"A":[103],"significant":[104,137],"(P<.01":[105],"versus":[106],"placebo)":[107],"drop":[108],"blood":[110,178],"(diastolic":[112],"systolic)":[114],"observed":[116,173,216],"all":[122],"groups,":[124],"trough-peak":[127],"ratio":[128],"greater":[129],"than":[130,227],"0.8,":[131],"high":[132],"response":[133],"rate,":[134],"dose-response":[138],"relationship":[139],"(P<.001).":[140],"The":[141,210],"full":[142],"antihypertensive":[143,198],"effect":[144,176],"achieved":[148],"within":[149],"1":[150],"associated":[156],"slight":[159],"dose-dependent":[160],"decrease":[161],"increase":[166],"PQ":[168,181],"time.":[169],"Clear":[170],"dissociation":[171],"between":[174],"time":[182],"when":[183],"concentration-effect":[184],"evaluated.":[187],"These":[188],"results":[189],"indicate":[190],"is":[193],"an":[194,253],"effective":[195],"well-tolerated":[197],"compound":[199],"100":[206],"daily.":[209],"incidence":[211],"treatment-related":[213],"adverse":[214,254],"events":[215],"25-,":[219],"50-,":[220],"100-mg":[222],"dose":[223,240],"groups":[224],"lower":[226],"group,":[231,241],"but":[232],"it":[233],"slightly":[235],"higher":[236],"150-mg":[239],"three":[243],"from":[245],"this":[246],"prematurely":[249],"withdrawn":[250],"because":[251],"event.":[255]},"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}